Literature DB >> 16172090

Topiramate in opiate withdrawal- comparison with clonidine and with carbamazepine/mianserin.

Daniele Fabio Zullino1, Sonia Krenz, Grégoire Zimmerman, Amos Miozzari, Rajini Rajeswaran, Stéphane Kolly, Yasser Khazaal.   

Abstract

UNLABELLED: There are some rationales for developing anticonvulsants for the treatment of substance abuse. The blockade of the AMPA/kainate subtype of glutamate receptor by topiramate may be of particular interest, as preclinical studies of withdrawal from opioids suggest that whilst AMPA-receptor antagonists may not be able to prevent tolerance or dependence from developing, they may ameliorate both physical and emotional consequences of withdrawal.
METHODS: Ten consecutively admitted patients treated with topiramate were compared in a retrospective naturalistic drug utilization observation study with 10 consecutively admitted patients treated with clonidine and with 10 consecutively admitted patients treated with a carbamazepine/ mianserin combination.
RESULTS: In 9 cases of the clonidine group and in 7 carbamazepine/mianserin treated patients the dose had been reduced, whereas this occurred in only 2 topiramate treated patients (p < 0.01). Patients in the topiramate group received less p.r.n. myorelaxant medication than the two other groups, and there was a significant difference between the three groups with regard to p.r.n. analgesics (p < 0.05), topiramate and clonidine treated patients receiving fewer analgesics than the carbamazepine/mianserin group.
CONCLUSIONS: Compared to clonidine and carbamazepine/mianserin, a detoxification scheme using high initial and then decreasing doses of topiramate appeared to be appropriate for most patients and as associated with less analgesic and myorelaxant comedication, indicating a more promising efficacy at the used doses.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 16172090     DOI: 10.1300/j465v25n04_04

Source DB:  PubMed          Journal:  Subst Abus        ISSN: 0889-7077            Impact factor:   3.716


  8 in total

1.  Topiramate impairs cognitive function in methadone-maintained individuals with concurrent cocaine dependence.

Authors:  Olga Rass; Annie Umbricht; George E Bigelow; Eric C Strain; Matthew W Johnson; Miriam Z Mintzer
Journal:  Psychol Addict Behav       Date:  2014-11-03

2.  Regarding topiramate for alcohol dependence.

Authors:  Adegboyega Oyemade
Journal:  Psychiatry (Edgmont)       Date:  2006-07

Review 3.  Topiramate in the treatment of substance-related disorders: a critical review of the literature.

Authors:  Ann K Shinn; Shelly F Greenfield
Journal:  J Clin Psychiatry       Date:  2010-03-09       Impact factor: 4.384

Review 4.  Role of the glutamatergic system in nicotine dependence : implications for the discovery and development of new pharmacological smoking cessation therapies.

Authors:  Matthias E Liechti; Athina Markou
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

5.  Pregabalin abuse among opiate addicted patients.

Authors:  Martin Grosshans; Tagrid Lemenager; Christian Vollmert; Nina Kaemmerer; Rupert Schreiner; Jochen Mutschler; Xenija Wagner; Falk Kiefer; Derik Hermann
Journal:  Eur J Clin Pharmacol       Date:  2013-08-30       Impact factor: 2.953

6.  Effect of five common anticonvulsant drugs on naloxone-precipitated morphine withdrawal in mice.

Authors:  V Hajhashemi; M Abed-Natanzi
Journal:  Res Pharm Sci       Date:  2011-01

7.  Topiramate in the treatment of compulsive sexual behavior: case report.

Authors:  Yasser Khazaal; Daniele Fabio Zullino
Journal:  BMC Psychiatry       Date:  2006-05-23       Impact factor: 3.630

Review 8.  It's MORe exciting than mu: crosstalk between mu opioid receptors and glutamatergic transmission in the mesolimbic dopamine system.

Authors:  Elena H Chartoff; Hilary S Connery
Journal:  Front Pharmacol       Date:  2014-05-27       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.